Source: Fortune
Summary
The luxury sector is facing challenges due to the conflict in the Middle East, but the emergence of AI and weight-loss medications like GLP-1s has created new opportunities. According to Bain & Co’s Luxury Monitor, growth in the sector has dipped slightly (-1%) year on year, with estimates for Q1 2026 coming in at -3% on a constant exchange rate. However, the use of GLP-1 weight-loss medications has driven consumption, particularly in the soft luxury category. Luxury brands are also facing the challenge of broadening their client base and being more inclusive, as the use of GLP-1s has led to a shift towards higher-quality products and experiences.
Our Reading
The numbers tell one story.
Luxury brands are shrinking their clothing size ranges, with 97.6% of looks presented in the Fall/Winter 2026 season being in “straight sizes” of U.S. 0-4. The use of GLP-1s presents an opportunity for luxury brands, but also raises questions about inclusivity. Brands are focusing on the top 1% of wealth, but are not capitalizing on the value of the market where there is the vast majority. The GLP-1 factor also extends to luxury experiences, with diners eating less but shifting to higher-quality dining.
The luxury sector is caught between exclusivity and accessibility, with brands struggling to balance high-end quality with broader appeal.
Author: Evan Null
